Company Sector
Tumor DNA Vaccines
Tumor DNA Vaccines is a company sector tag on BioPharmSignal. This page groups public biotech and healthcare companies associated with Tumor DNA Vaccines, making it easier to scan related businesses, compare peers, and follow companies exposed to the same modality, disease area, or development theme.
Why watch Tumor DNA Vaccines
This page combines a company index, a watch action, and the newest relevant feed items in one place so readers can monitor a biotech theme without scanning each company one by one.
Latest Tumor DNA Vaccines news
The latest feed items from companies currently grouped under Tumor DNA Vaccines.
- 01
INOINOVIO Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
Source: Inovio Pharmaceuticals
- 02
INOInovio Announces Initiation of “MD Anderson’s HPV-Related Cancers Moon Shot” Phase 2 Trial in New HPV Indications
Source: Inovio Pharmaceuticals
- 03
INOInovio, DNA 암호화 단일클론 항체(dMAb™) 플랫폼의 효능 입증하는 임상전 논문 3건과 2019년 첫 임상시험 계획 발표
Source: Inovio Pharmaceuticals
- 04
INOイノビオ社、3件の前臨床試験で同社のDNAコード化モノクローナル抗体 (dMAb™) プラットフォームの効力をさらに実証し、2019年初旬の初回臨床試験に向けて準備を進める
Source: Inovio Pharmaceuticals
- 05
INOInovio在三項臨床前試驗結果文獻中進一步顯示Inovio的DNA編碼單克隆抗體（dMAb™）平台的療效，並準備在2019年初進行首次臨床試驗
Source: Inovio Pharmaceuticals
- 06
- 07
INOInovio Prepares for Growth & Commercialization With Leadership Appointments
Source: Inovio Pharmaceuticals
- 08
INOInovio Pharmaceuticals Reports 2018 Third Quarter Financial Results
Source: Inovio Pharmaceuticals
- 09
INOInovio Pharmaceuticals to Participate in Upcoming Investment Conferences
Source: Inovio Pharmaceuticals
- 10
INOInovio의 HIV 백신 PENNVAX®-GP, 피내 투여 시 강력하고 지속적인 항체, T세포 면역 반응 나타내
Source: Inovio Pharmaceuticals
- 11
- 12
INOInovio Pharmaceuticals, 2018년 11월 8일 3분기 실적발표 실시
Source: Inovio Pharmaceuticals
- 13
INOInovio Pharmaceuticals to Report Third Quarter 2018 Financial Results on November 8, 2018
Source: Inovio Pharmaceuticals
- 14
INOInovio, INO-5150의 전립선암 환자 무진행 생존율 향상 및 PSA 배가 시간 지연 효과 발표
Source: Inovio Pharmaceuticals
- 15
- 16
INOInovio의 DNA 암호화 단일클론 항체(dMAb™) 플랫폼, 긍정적 데이터 도출과 함께 특허 및 연구비 획득
Source: Inovio Pharmaceuticals
- 17
INOイノビオ社によるDNAコード･モノクローナル抗体 (dMAb™) プラットフォーム、有望なデータ、特許、助成金を取得して進歩する
Source: Inovio Pharmaceuticals
- 18
INOInovio的DNA编码单克隆抗体（dMAbTM）平台在积极数据、专利和赠款方面取得进展
Source: Inovio Pharmaceuticals
- 19
INOInovio’s DNA-Encoded Monoclonal Antibody (dMAb™) Platform Moves Ahead with Positive Data, Patents and Grants
Source: Inovio Pharmaceuticals
- 20
INOInovio’s Ebola Vaccine Provides 100% Protection And Elicits Long-Lasting Immune Responses in Preclinical Studies
Source: Inovio Pharmaceuticals
Companies in Tumor DNA Vaccines
1 company tagged with Tumor DNA Vaccines.
Frequently Asked Questions
What does the Tumor DNA Vaccines sector include?
Tumor DNA Vaccines is a company sector tag on BioPharmSignal. This page groups public biotech and healthcare companies associated with Tumor DNA Vaccines, making it easier to scan related businesses, compare peers, and follow companies exposed to the same modality, disease area, or development theme.
How many companies are currently tagged with Tumor DNA Vaccines?
1 company are currently grouped under Tumor DNA Vaccines on BioPharmSignal.
Which companies are most visible in the Tumor DNA Vaccines group right now?
INO are among the companies currently shown on this sector page.
How can I watch news for Tumor DNA Vaccines?
Use the Watch button on this page to subscribe to Tumor DNA Vaccines headlines and related company updates through your BioPharmSignal saved filters.
What kinds of updates usually appear for Tumor DNA Vaccines?
The livefeed typically surfaces company press releases, clinical readouts, FDA and regulatory updates, partnerships, financings, and commercialization developments tied to companies in Tumor DNA Vaccines.